PCN342 Real World Healthcare Resources Utilization Associated with the Management of Patients with Relapsed or Refractory Multiple Myeloma in Spain: The Charismma Study

Abstract

To describe the healthcare resource utilization of real-world patients with relapsed or refractory multiple myeloma (RRMM) under active treatment. Multicenter, cross-sectional study of patients routinely treated in Spain between 2017 and 2018. Data were retrieved from either the clinical records or a structured interview. The study included 276 patients with RRMM (mean age 67.4 years; SD 10.5), enrolled with a median of 1.61 months (Q1-Q3 0.74-3.14) after the last relapse. At enrollment, 119 (43.3%), 71 (25.8%), and 85 (30.9%) patients initiated second-line, third-line, and ≥fourth-line therapy, respectively; 12 patients underwent stem cell transplant. Most patients were retired (n=179; 65.1%) and lived in urban areas (n=209; 75.7%) with their relatives (n=235; 85.8%); 79 (28.7%) patients had some degree of dependence. Patients lived 0.5-to-530 Km away from the healthcare center (median 9.0; Q1-Q3 3-30); 183 patients (67.8%) traveled to the hospital in their private vehicle. Last relapse management required a mean of 4.1 trips every month (SD 4.8) to the healthcare center, with a monthly cost ranging from 0 to 1,160€ (median 15.8; Q1-Q3 5.0-42.0). Along this relapse, 60/155 (38.7%) required to attend the emergency department, and 92/155 (59.4%) were admitted to the hospital (mean length of stay 16 days); 270 patients (97.8%) visited the hematologist, a median of 4 times (Q1-Q3 2-6). Median (Q1-Q3) number of visits alone and with a caregiver were 2 (2-4) and 4 (2-6), respectively; 112 caregivers (54.4%) were employed. Aside from the specialist, 60 patients (21.7%) visited their GP, a median of 1 time (1-2.5) alone and 2 (1-4) accompanied; 227 patients (82.2%) required an imaging exam: 43.2% x-ray, 29.5% computerized tomography, and 20.7% magnetic resonance. RRMM is associated with a significant societal burden and healthcare resources utilization, which affects patients and caregivers. These factors should be considered when prescribing treatments for RRMM.